


*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**SINO BIOPHARMACEUTICAL LIMITED**  
**中國生物製藥有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

*Website: [www.sinobiopharm.com](http://www.sinobiopharm.com)*

**(Stock code: 1177)**

**VOLUNTARY ANNOUNCEMENT**  
**APPROVAL OF “ADALIMUMAB SOLUTION FOR INJECTION”**  
**FOR MARKETING**

The board of directors (the “**Board**”) of Sino Biopharmaceutical Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) announces that “Adalimumab Solution for Injection (阿達木單抗注射液)” (Brand name: Taibowei (泰博維)), the first biosimilar drug developed by the Group for the treatment of the three major indications of rheumatoid arthritis, ankylosing spondylitis and psoriasis, has obtained drug registration certificate granted by the National Medical Products Administration of the PRC. Clinical studies have shown that Taibowei is safer than similar products and can significantly reduce the incidence of disease manifestation beyond joints in patients. The launch of Taibowei, the first biosimilar drug developed by the Group, is a strong addition to the Group’s autoimmune pipeline and will accelerate the unlocking of the market potential of adalimumab in the PRC.

As the sixth adalimumab drug to be marketed in the PRC, Taibowei’s clear differentiation is reflected in its safety profile. Clinical studies have shown that Taibowei is comparable to the original adalimumab in terms of pharmacokinetics, safety, tolerability and immunogenicity. In the treatment of active ankylosing spondylitis, Taibowei has outperformed the original adalimumab in terms of liver safety. The original adalimumab has been the world’s top-selling drug for nine years; however, in the PRC, due to relatively less approved indications, high selling price and other factors, the usage rate of the drug among Chinese patients is less than 2%. The approval for launch of Taibowei will greatly improve the drug accessibility of patients at a competitive market price.

In addition, the Group is currently the only pharmaceutical company with both small molecule (tofacitinib) and macromolecule (adalimumab) anti-rheumatic drugs in the PRC. These two types of anti-rheumatic drugs with different mechanisms can complement each other in clinical use to satisfy the different treatment needs of a wider range of patients. The Group will capitalize on the trend of “care for comorbidity” to promote the “integration of diagnosis and treatment” of orthopedics and rheumatology and the expansion of new patients, with a view to benefiting more patients.

By order of the Board  
**Sino Biopharmaceutical Limited**  
**Tse, Theresa Y Y**  
*Chairwoman*

Hong Kong, 20 January 2022

*As at the date of this announcement, the Board of the Company comprises nine executive directors, namely Ms. Tse, Theresa Y Y, Mr. Tse Ping, Ms. Cheng Cheung Ling, Mr. Tse, Eric S Y, Mr. Tse Hsin, Mr. Li Yi, Mr. Wang Shanchun, Mr. Tian Zhoushan and Ms. Li Mingqin and five independent non-executive directors, namely Mr. Lu Zhengfei, Mr. Li Dakui, Ms. Lu Hong, Mr. Zhang Lu Fu and Dr. Li Kwok Tung Donald.*